Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04908514 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis
A Phase 2 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04908514 is a Phase 2 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 10 participants.
The verdict
NCT04908514, a Phase 2 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Plaque Psoriasis
Interventions
- DRUG ADX-629
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-05-07 |
| Est. Completion | 2022-01-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04908514
The ClinicalTrials.gov registry entry for NCT04908514 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADX-629 is the first listed.
NCT04908514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04908514 about?
NCT04908514 is a clinical study titled "A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis". A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Plaque Psoriasis
What is the current status of trial NCT04908514?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2021-05-07. Estimated completion is 2022-01-21.
What interventions are being tested in trial NCT04908514?
The interventions under investigation include: ADX-629 (DRUG).
Who is sponsoring clinical trial NCT04908514?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.